AB133321

Anti-eIF-6 antibody [EPR6513]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(1 Publication)

Rabbit Recombinant Monoclonal eIF-6 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.

View Alternative Names

EIF3A, ITGB4BP, OK/SW-cl.27, EIF6, Eukaryotic translation initiation factor 6, eIF-6, B(2)GCN homolog, B4 integrin interactor, CAB, p27(BBP)

2 Images

Unknown

Western blot - Anti-eIF-6 antibody [EPR6513] (AB133321)

All lanes:

Western blot - Anti-eIF-6 antibody [EPR6513] (ab133321) at 1/10000 dilution

Lane 1:

HeLa cell lysate at 10 µg

Lane 2:

293T cell lysate at 10 µg

Lane 3:

HepG2 cell lysate at 10 µg

Lane 4:

K562 cell lysate at 10 µg

Secondary

All lanes:

Goat anti-Rabbit HRP at 1/2000 dilution

Predicted band size: 27 kDa

false

OI-RD Scanning - Anti-eIF-6 antibody [EPR6513] (AB133321)

OI-RD Scanning

Unknown

OI-RD Scanning - Anti-eIF-6 antibody [EPR6513] (AB133321)

We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR6513

Isotype

IgG

Carrier free

Reacts with

Human

Applications

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/10000 - 1/50000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purity

Tissue culture supernatant

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Storage information

Stable for 12 months at -20°C

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

EIF-6 also known as eukaryotic translation initiation factor 6 is a protein involved in the control of ribosomal function. The protein has a molecular mass of approximately 25 kDa and is expressed in the cytoplasm of eukaryotic cells. It acts by binding to the 60S ribosomal subunit and preventing premature association with the 40S subunit. This regulation ensures the proper assembly and function of the 80S ribosome essential for protein synthesis.

Biological function summary

Eukaryotic translation initiation factor 6 plays a significant role in ribosome biogenesis and translation initiation. It functions as a part of the ribosomal precursor complex facilitating the formation of functional 60S ribosomal units. Through its action eIF-6 modulates cellular protein synthesis rates impacting cell growth and proliferation. Additionally eIF-6 influences cellular responses to nutrient availability stressing its role in metabolic regulation.

Pathways

Eukaryotic translation initiation factor 6 is integral to the mTOR signaling pathway and ribosome biogenesis pathway. The mTOR pathway involves proteins like mTOR itself and S6 kinase which connect to eIF-6-mediated regulation of protein synthesis. eIF-6 maintains the balance between ribosome production and protein translation rates coordinating cellular growth with environmental cues.

Aberrations in eukaryotic translation initiation factor 6 levels link to cancer and metabolic diseases. Overexpression of eIF-6 can lead to excessive protein synthesis contributing to oncogenic processes by promoting unchecked cell proliferation. Additionally the dysregulation of eIF-6 can affect the mTOR pathway contributing to metabolic dysfunction. Connections between eIF-6 and other proteins like cyclin D1 highlight its impact on tumorigenesis and cell cycle control.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit to form the 80S initiation complex in the cytoplasm (PubMed : 10085284, PubMed : 14654845, PubMed : 21536732, PubMed : 32669547). Behaves as a stimulatory translation initiation factor downstream insulin/growth factors. Is also involved in ribosome biogenesis. Associates with pre-60S subunits in the nucleus and is involved in its nuclear export. Cytoplasmic release of TIF6 from 60S subunits and nuclear relocalization is promoted by a RACK1 (RACK1)-dependent protein kinase C activity (PubMed : 10085284, PubMed : 14654845, PubMed : 21536732). In tissues responsive to insulin, controls fatty acid synthesis and glycolysis by exerting translational control of adipogenic transcription factors such as CEBPB, CEBPD and ATF4 that have G/C rich or uORF in their 5'UTR. Required for ROS-dependent megakaryocyte maturation and platelets formation, controls the expression of mitochondrial respiratory chain genes involved in reactive oxygen species (ROS) synthesis (By similarity). Involved in miRNA-mediated gene silencing by the RNA-induced silencing complex (RISC). Required for both miRNA-mediated translational repression and miRNA-mediated cleavage of complementary mRNAs by RISC (PubMed : 17507929). Modulates cell cycle progression and global translation of pre-B cells, its activation seems to be rate-limiting in tumorigenesis and tumor growth (By similarity).

See full target information EIF6

style

left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

International journal of nanomedicine 20:8343-8357 PubMed40599399

2025

Combination of Ketorolac Tromethamine and Prednisolone-Loaded PLGA Nanocomposite for Effective Chronic Pain Relief in Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Tuyet-Nhi Do,Yen-Chin Liu,Yu-Che Chuang,Tsung-Lin Tsai,Ping-Ching Wu

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-eIF-6 antibody [EPR6513]

Western blot - Anti-eIF-6 antibody [EPR6513] (AB133321)

OI-RD Scanning - Anti-eIF-6 antibody [EPR6513] (AB133321)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purity

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (1)

Alternative Products

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product promise